IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

The authors recommended having awareness of potential psychiatric AEs with the use of biologics in treating psoriasis or psoriatic arthritis, guiding toward more personalized and comprehensive ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Advancements in biologics, personalized medicine, and rising global prevalence drive the psoriasis treatment market's exponential growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment ...